Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes - 22/08/19
Julie Rouette, MSc, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Antonios Douros, MD, PhD, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada and Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Hui Yin, MSc, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; Oriana Hoi Yun Yu, MD, MSc, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital and Division of Endocrinology, Jewish General Hospital, Montreal, Canada; Kristian B. Filion, PhD, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, and Department of Medicine and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Laurent Azoulay, PhD, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, and Department of Epidemiology, Biostatistics, and Occupational Health and Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 81 - N° 4S1
P. AB47 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?